Literature DB >> 18223026

Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression.

L Burchill1, E Velkoska, R G Dean, R A Lew, A I Smith, V Levidiotis, L M Burrell.   

Abstract

Patients with kidney failure are at high risk of a cardiac death and frequently develop left ventricular hypertrophy (LVH). The mechanisms involved in the cardiac structural changes that occur in kidney failure are yet to be fully delineated. Angiotensin-converting enzyme (ACE) 2 is a newly described enzyme that is expressed in the heart and plays an important role in cardiac function. This study assessed whether ACE2 plays a role in the cardiac remodelling that occurs in experimental acute kidney injury (AKI). Sprague-Dawley rats had sham (control) or subtotal nephrectomy surgery (STNx). Control rats received vehicle (n = 10), and STNx rats received the ACE inhibitor (ACEi) ramipril, 1 mg kg(-1) day(-1) (n = 15) or vehicle (n = 13) orally for 10 days after surgery. Rats with AKI had polyuria (P < 0.001), proteinuria (P < 0.001) and hypertension (P < 0.001). Cardiac structural changes were present and characterized by LVH (P < 0.001), fibrosis (P < 0.001) and increased cardiac brain natriuretic peptide (BNP) mRNA (P < 0.01). These changes occurred in association with a significant increase in cardiac ACE2 gene expression (P < 0.01) and ACE2 activity (P < 0.05). Ramipril decreased blood pressure (P < 0.001), LVH (P < 0.001), fibrosis (P < 0.01) and BNP mRNA (P < 0.01). These changes occurred in association with inhibition of cardiac ACE (P < 0.05) and a reduction in cardiac ACE2 activity (P < 0.01). These data suggest that AKI, even at 10 days, promotes cardiac injury that is characterized by hypertrophy, fibrosis and increased cardiac ACE2. Angiotensin-converting enzyme 2, by promoting the production of the antifibrotic peptide angiotensin(1-7), may have a cardioprotective role in AKI, particularly since amelioration of adverse cardiac effects with ACE inhibition was associated with normalization of cardiac ACE2 activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223026     DOI: 10.1113/expphysiol.2007.040386

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  37 in total

Review 1.  Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.

Authors:  Lijun Shi; Caiping Mao; Zhice Xu; Lubo Zhang
Journal:  Drug Discov Today       Date:  2010-02-17       Impact factor: 7.851

Review 2.  Acute kidney injury: the beginning of the end of the dark ages.

Authors:  Pamela D Winterberg; Christopher Y Lu
Journal:  Am J Med Sci       Date:  2012-10       Impact factor: 2.378

Review 3.  New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism.

Authors:  Carlos M Ferrario
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

Review 4.  The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function.

Authors:  Carlos M Ferrario; Jasmina Varagic
Journal:  Am J Physiol Renal Physiol       Date:  2010-04-07

5.  The influence of folic acid-induced acute kidney injury on cardiac function and redox status in rats.

Authors:  Tomislav Nikolic; Dejan Petrovic; Stevan Matic; Tamara Nikolic Turnic; Jovana Jeremic; Katarina Radonjic; Ivan Srejovic; Vladimir Zivkovic; Stefani Bolevich; Sergey Bolevich; Vladimir Jakovljevic
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-27       Impact factor: 3.000

6.  Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.

Authors:  Jasmina Varagic; Sarfaraz Ahmad; Jessica L VonCannon; Norihito Moniwa; K Bridget Brosnihan; Jan Wysocki; Daniel Batlle; Carlos M Ferrario
Journal:  Am J Hypertens       Date:  2013-03-04       Impact factor: 2.689

7.  Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2.

Authors:  Chandana B Herath; John S Lubel; Zhiyuan Jia; Elena Velkoska; David Casley; Lindsay Brown; Chris Tikellis; Louise M Burrell; Peter W Angus
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-23       Impact factor: 4.052

8.  Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury.

Authors:  Etienne Gayat; Alexa Hollinger; Alain Cariou; Nicolas Deye; Antoine Vieillard-Baron; Samir Jaber; Benjamin G Chousterman; Qin Lu; Pierre François Laterre; Xavier Monnet; Michael Darmon; Marc Leone; Bertrand Guidet; Romain Sonneville; Jean-Yves Lefrant; Marie-Céline Fournier; Matthieu Resche-Rigon; Alexandre Mebazaa; Matthieu Legrand
Journal:  Intensive Care Med       Date:  2018-05-15       Impact factor: 17.440

9.  Angiotensin converting enzyme 2 (ACE2) activity in fetal calf serum: implications for cell culture research.

Authors:  J S Lubel; C B Herath; E Velkoska; D J Casley; L M Burrell; P W Angus
Journal:  Cytotechnology       Date:  2009-02-18       Impact factor: 2.058

10.  Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition.

Authors:  Elena Velkoska; Rachael G Dean; Luke Burchill; Vicki Levidiotis; Louise M Burrell
Journal:  Clin Sci (Lond)       Date:  2010-02       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.